Antibiotic Resistance

Definition
Antimicrobial resistance is the ability of microorganisms that cause disease to withstand attack by antimicrobial medicines. (WHO) Antibiotic resistance is the ability of a microorganism to withstand the effects of an antibiotic. (Science Daily) Antibiotic resistance occurs when an antibiotic has lost its ability to effectively control or kill bacterial growth; in other words, the bacteria are "resistant" and continue to multiply in the presence of therapeutic levels of an antibiotic. (APUA = Aliance for the Prudent Use of Antibiotic)

Introduction
In the past 60 years, antibiotics have been critical in the fight against infectious disease caused by bacteria and other microbes. Antimicrobial chemotherapy has been a leading cause for the dramatic rise of average life expectancy in the Twentieth Century. However, disease-causing microbes that have become resistant to antibiotic drug therapy are an increasing public health problem. Bacteria and other microbes that cause infections have developed several ways to resist antibiotics and other antimicrobial drugs.

The first signs of antibiotic resistance

Resistance to penicillin in some strains of staphylococci was recognized almost immediately after introduction of the drug in 1946 In the late 1940s, resistance to streptomycin, chloramphenicol and tetracycline was noted. By 1953, during a Shigella outbreak in Japan, a strain of the dysentery bacillus (Shigella dysenteriae) was isolated which was multiple drug resistant, exhibiting resistance to chloramphenicol, tetracycline, streptomycin and the sulfonamides.

 Evidence also began to accumulate that bacteria could pass genes for drug resistance between strains and even between species. For example, antibiotic-resistance genes of staphylococci are carried on plasmids that can be exchanged with Bacillus, Streptococcus and Enterococcus providing the means for acquiring additional genes and gene combinations. Some are carried on transposons, segments of DNA that can exist either in the chromosome or in plasmids.

Multiple drug resistant organisms

Multiple drug resistant organisms are resistant to treatment with several, often unrelated, antimicrobial agents as described above in Shigella. Some of the most important types of multiple drug resistant organisms that have been encountered include: MRSA - methicillin/oxacillin-resistant Staphylococcus aureus VRE - vancomycin-resistant enterococci ESBLs - extended-spectrum beta-lactamases (which are resistant to cephalosporins and monobactams) PRSP - penicillin-resistant Streptococcus pneumoniae multidrug resistant (e.g.: Multidrug resistant Enterococci, MDRE), extremely resistant (e.g.: Extremely drug resistant Mycobacterium tuberculosis, XDRTB) or super resistant types (e.g.: Super drug resistant Enterococci, SDRE).

Bacterial mechanisms of antibiotic resistance

Several mechanisms have evolved in bacteria which confer them with antibiotic resistance.
reduced drug uptake active pumping of drugs out of the cell. This is the mechanism of
resistance to tetracycline

enzymatic alteration of the antibiotic A specific enzyme modifies the

antibiotic in a way that it loses its activity. In the case of streptomycin, the antibiotic is chemically modified so that it will no longer bind to the ribosome to block protein synthesis An enzyme is produced that degrades the antibiotic, thereby inactivating it. For example, the penicillinases are a group of beta-lactamase enzymes that cleave the beta lactam ring of the penicillin molecule.

modification of targets drug sequestering by protein binding overproduction of the target metabolic bypass of the targeted pathway

There are many mechanisms by which bacteria evade antibiotic treatment: reduced drug uptake; active pumping of drugs out of the cell; enzymatic alteration of the antibiotic; modification of targets; drug sequestering by protein binding; overproduction of the target metabolic; bypass of the targeted pathway

Antibiotic
Chloramphenicol Tetracycline

Method of resistance
reduced uptake into cell active efflux from the cell

-lactams, Erythromycin, eliminates or reduces binding of Lincomycin antibiotic to cell target

-lactams, Aminoglycosides, Chloramphenicol Sulfonamides, Trimethoprim Sulfonamides, Trimethoprim enzymatic cleavage or modification to inactivate antibiotic molecule

metabolic bypass of inhibited reaction overproduction of antibiotic target (titration)

The acquisition and spread of antibiotic resistance in bacteria

Inherent (natural) resistance. Bacteria may be inherently resistant to an antibiotic. For example, an organism lacks a transport system for an antibiotic; or an organism lacks the target of the antibiotic molecule; or, as in the case of Gram-negative bacteria, the cell wall is covered with an outer membrane that establishes a permeability barrier against the antibiotic. Acquired resistance. Several mechanisms are developed by bacteria in order to acquire resistance to antibiotics. All require either the modification of existing genetic material or the acquisition of new genetic material from another source.

 Vertical gene transfer

The spontaneous mutation frequency for antibiotic resistance is on the order of about of about 10-8- 10-9. This means that one in every every 108-109 bacteria in an infection will develop resistance through the process of mutation. In E. coli, it has been estimated that streptomycin resistance is acquired at a rate of approximately 10-9 when exposed to high concentrations of streptomycin. Although mutation is a very rare event, the very fast growth rate of bacteria and the absolute number of cells attained means that it doesn't take long before resistance is developed in a population. Once the resistance genes have developed, they are transferred directly to all the bacteria's progeny during DNA replication. This is known as vertical gene transfer or vertical evolution. The process is strictly a matter of Darwinian evolution driven by principles of natural selection: a spontaneous mutation in the bacterial chromosome imparts resistance to a member of the bacterial population. In the selective environment of the antibiotic, the wild type (non mutants) are killed and the resistant mutant is allowed to grow and flourish

Schematic representation of how antibiotic resistance evolves via natural selection: The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria.

The legend indicates the resistance levels of individuals.

Mutation Causes of Drug Resistance

Gene Transfer Facilitates Drug Resistance

 Horizontal gene transfer

Another mechanism beyond spontaneous mutation is responsible for the acquisition of antibiotic resistance.
Lateral or horizontal gene transfer (HGT) is a process whereby genetic material contained in small packets of DNA can be transferred between individual bacteria of the same species or even between different species.

There are at least three possible mechanisms of HGT, equivalent to the three processes of genetic exchange in bacteria. These are transduction, transformation or conjugation.

Mechanisms of horizontal gene transfer (HGT) in bacteria

Societal, medical and agricultural practices that lead to antibiotic resistance

Antibiotics in food and water
Prescription drugs are not the only source of antibiotics in the environment. In the United States, antibiotics can be found in beef cattle, pigs and poultry. The same antibiotics then find their way into municipal water systems when the runoff from housing facilities and feedlots contaminates streams and groundwater. So it's a double hit: we get antibiotics in our food and drinking water, and we meanwhile promote bacterial resistance.

Routine feeding of antibiotics to animals is banned in the European Union and many other industrialized countries. Maybe they know something we don't.

 Indiscriminate use of antibiotics in agriculture and veterinary practice

The non-therapeutic use of antibiotics in livestock production makes up at least 60 percent of the total antimicrobial production in the United States. Irresponsible use of antibiotics in farm animals can lead to the development of resistance in bacteria associated with the animal or with people who eat the animal. Such resistance can then be passed on to human pathogens by mechanisms of HGT.

Of major concern is the use of antibiotics as feed additives given to farm animals to promote animal growth and to prevent infections (rather than cure infections). The use of an antibiotic in this way contributes to the emergence of antibiotic-resistant pathogens and reduces the effectiveness of the antibiotic to combat human infections.

Non-Therapuetic use
Unlike in humans, an even larger proportion of antibiotics produced for veterinary use are utilized in animal herds or flocks for purposes other than treatment. A report by the Union of Concerned Scientists estimated that in the United States alone, the livestock producers use about 24.6 million pounds of antimicrobials for nontherapeutic purposes, a volume about eight times greater than the 3 million pounds estimated use for human medicine (Mellon et al., 2001).

 Antibiotics as growth promotant was discovered in

the 1940s, when it was observed that chicks improve in growth when fed bacterial shells of Streptomyces aureofaciens from which antibiotics had been extracted.

In the olden days, prior to the use of antibiotics, a chicken looked like the one on the left. Today's chicken is fed a "healthy" dose of antibiotics and looks like the feller on the right. By they way, today's chicken cannot walk.

It is not uncommon for veterinarians to give antibiotics to animals that are not currently ill with a particular disease, but are at high risk of acquiring an infection. For example, an animal may be treated with antibiotics after having undergone surgery or injurious trauma (prophylaxis) or herds and flocks may be given antibiotics if they are at risk of suffering an outbreak of infectious disease due to exposure to disease agents or extremely unfavorable host or environmental conditions (metaphylaxis)

 Antibiotic resistance in genetically modified crops

Antibiotic-resistance genes are used as "markers" in genetically modified crops. The genes are inserted into the plant in early stages of development to in order to detect specific genes of interest. (e.g. kanamycin* resistance gene) The antibiotic-resistance genes have no further role to play, but they are not removed from the final product. This practice has met with criticism because of the potential that the antibiotic-resistance genes could be acquired by microbes in the environment. In some cases these marker genes confer resistance to front-line antibiotics such as the beta-lactams and aminoglycosides.

ARMG Antibiotic Resistance Marker Gene (genetics)

 Inappropriate use of antibiotics in the medical environment One problem is the casual use of antibiotics in medical situations where they are of no value. This is the fault of both health care workers and patients. Prescribers sometimes thoughtlessly prescribe 'informed' demanding patients with antibiotics. This leads to use of antibiotics in circumstances where they are of not needed, e.g. viral upper respiratory infections such as cold and flu, except when there is serious threat of secondary bacterial infection. Another problem is patient failure to adhere to regimens for prescribed antibiotics.

 Patients and doctors need to realize their responsibility when they begin an antibiotic regimen to combat an infectious disease. There are several measures that should be considered:
Patients should not take antibiotics for which there is no medical value (corollary: doctors should not prescribe antibiotics for which there is no medical value).
Patients should adhere to appropriate prescribing guidelines and take antibiotics until they have finished. Patients should be give combinations of antibiotics, when necessary, to minimize the development of resistance to a single antibiotic (as in the case of TB). Patients need to be given another antibiotic or combination of antibiotics if the first is not working.

Combating antibiotic resistance

Search for new antibiotics. To combat the occurrence of
resistant bacteria, biotechnology and pharmaceutical companies must constantly research, develop and test new antimicrobials in order to maintain a pool of effective drugs on the market.

Stop the use of antibiotics as growth-promoting substances in farm animals. Of major concern is the use of
antibiotics as feed additives given to farm animals to promote animal growth and to prevent infections rather than cure infections. The use of such antibiotics contributes to the emergence of antibioticresistant bacteria that threaten human health and decreases the effectiveness of the same antibiotics used to combat human infections.

Use the right antibiotic in an infectious situation as determined by antibiotic sensitivity testing, when
possible.

 Stop unnecessary antibiotic prescriptions. Unnecessary

prescriptions of antibiotics are made when antibiotics are prescribed for viral infections (antibiotics have no effect on viruses). This gives the opportunity for indigenous bacteria (normal flora) to acquire resistance that can be passed on to pathogens.

Finish antibiotic prescriptions. Unfinished antibiotic

prescriptions may leave some bacteria alive or may expose them to sub-inhibitory concentrations of antibiotics for a prolonged period of time. Mycobacterium tuberculosis is a slow growing bacteria which infects the lung and causes tuberculosis. This disease kills more adults than any other infectious disease. Due to the slow growing nature of the infection, treatment programs last for months or even years. This has led to many cases on unfinished prescriptions and 5% of strains now observed are completely resistant to all known treatments and hence incurable.

Years of research and billions of dollars are pulled out to bring out an antibiotic. And the resistance is evolved, just like that (The sad part). The best explanation provided is natural selection. The normal mutation rate of the organism allows an occasional microbe to be generated that is resistant to the antibiotic. This population extends over a period of time replacing the original sensitive strain.

 Not only is there a problem in finding new antibiotics to fight old diseases (because resistant strains of bacteria have emerged), there is a parallel problem to find new antibiotics to fight new diseases. In the past three decades, many "new" bacterial diseases have been discovered (E. coli O157:H7 gastric ulcers, Lyme disease, toxic shock syndrome, "skin-eating" streptococci). Already broad patterns of resistance exist in these pathogens, and it seems likely that we will soon need new antibiotics to replace the handful that are effective now against these bacteria, especially as resistance begins to emerge among them in the selective environment antibiotic chemotherapy.